NICE (UK) terminated evaluation for Rhopressa (netarsudil) treating open-angle glaucoma or ocular hypertension – Santen

NICE (UK): NICE is unable to make a recommendation about the use in the NHS of netarsudil for treating open-angle glaucoma or ocular hypertension in adults.

This is because Santen UK & Ireland has confirmed that it does not intend to make an evidence submission for the evaluation. It considers that there is not enough evidence to provide an evidence submission and it will not be launching the technology at this time. NICE will review the position if the company decides that it wants to make an evidence submission.